Industry News
PolyNovo in $11m deal with Medtronic
PolyNovo Biomaterials, jointly owned by CSIRO and Xceed Biotechnology (ASX:XBL) has signed a partnering and licensing agreement potentially worth more than AUD$11 million with giant US-based device maker Medtronic. [ + ]
Epitan opts for name change
Melbourne-based Epitan (ASX:EPT) is planning to change its name to Clinuvel Pharmaceuticals. [ + ]
New Peptech CEO excited by Australian opportunities
John Chiplin, the new CEO of Sydney biopharma Peptech (ASX:PTD), sees strong similarities between the state of Australia's biotechnology industry and California's nascent biotechnology industry in San Diego in the mid-1980s. [ + ]
Apollo completes phase Ib psoriasis trial data collection
Sydney-based biopharma Apollo Life Sciences (ASX:AOP) said no significant adverse side-effects were detected in a phase Ib trial of its topical psoriasis cream, developed from human-expressed protein. [ + ]
BioProspect raises $1.2m
Natural pesticide developer BioProspect (ASX:BPO) has raised AUD$1.2 million from its fully underwritten rights offer, where shareholders could subscribe for one new share, at a price of $0.02, and a free attaching option for every three shares held. [ + ]
CathRx pleased by positive catheter trial results
A clinical trial conducted by Sydney medical device company CathRx (ASX:CXD) has shown that its catheters can appropriately diagnose arrythmias when measuring electrical signals generated by the heart. [ + ]
Phosphagenics initiates anti-cancer compound animal trials
Melbourne's Phosphagenics (ASX:POH, AIM:PSG) will commence animal studies later this month on its patented anti-cancer compound. [ + ]
Metabolic CEO keen to prove worth of lead drugs
Metabolic Pharmaceuticals (ASX:MBP) CEO Dr Roland Scollay is feeling no pain as his Melbourne-based biopharmaceutical company heads into a potentially momentous year in the clinic for its two lead compounds, the anti-obesity drug AOD9604 and chronic neuropathic pain lead ACV1. [ + ]
Specialist centre for biotech training
Education and Training Minister Lynne Kosky visited the Box Hill Institute to launch BioSkills, the Specialist Centre in Biotechnology Training.
[ + ]CyGenics to open cord blood bank in India
Singapore-based, ASX-listed cell therapy company CyGenics (ASX:CYN) is the majority shareholder in a new Indian cord blood banking company, to be called CordLife Sciences (India), after an initial investment of AUD$850,000. [ + ]
Medical device industry pioneer Paul Trainor dies
Paul Trainor AO, 78, 'father of Australia's medical device industry' died on January 13, 2006. [ + ]
Virax sanguine on shortfall in $3.1m raising
Melbourne immunotherapy developer Virax Holdings (ASX:VHL) has raised $3.1 million through a rights issue for the further development of its HIV therapeutic vaccine, falling $700,000 short of the $3.8 million the company planned to raise. [ + ]
LCT to raise additional US and European capital
Following the successful placement of more than AUD$3 million worth of shares in the US earlier this month, cell therapy company Living Cell Technologies (ASX:LCT) has revealed plans to raise at least a further AUD$8 million through a second tranche of shares in the US and Europe. [ + ]
Sydney team patents new ES cell growth method
A research team at Sydney's Prince of Wales Hospital has developed and patented a technique for growing human embryonic stem (ES) cells without using animal-derived feeder cells. [ + ]
Canberra summit to explore Australia's genetic research prospects
Federal and state MPs are to get an insight into Australian genetic and genomic research capabilities and opportunities, at a national forum to be held in Canberra in February. [ + ]

